Bisphosphonates: Mechanism of Action and Role in Clinical Practice

Overview

Journal Mayo Clin Proc

Specialty General Medicine

Date 2008 Sep 9

PMID 18775204

Citations 570

Authors

Matthew T Drake

Bart L Clarke

Suneep Khosla

Affiliations

Soon will be listed here.

Abstract

Bisphosphonates are primary agents in the current pharmacological arsenal against osteoclast-mediated bone loss due to osteoporosis, Paget disease of bone, malignancies metastatic to bone, multiple myeloma, and hypercalcemia of malignancy. In addition to currently approved uses, bisphosphonates are commonly prescribed for prevention and treatment of a variety of other skeletal conditions, such as low bone density and osteogenesis imperfecta. However, the recent recognition that bisphosphonate use is associated with pathologic conditions including osteonecrosis of the jaw has sharpened the level of scrutiny of the current widespread use of bisphosphonate therapy. Using the key words bisphosphonate and clinical practice in a PubMed literature search from January 1, 1998, to May 1, 2008, we review current understanding of the mechanisms by which bisphosphonates exert their effects on osteoclasts, discuss the role of bisphosphonates in clinical practice, and highlight some areas of concern associated with bisphosphonate use.

Citing Articles

Bone Health in Paediatric Inflammatory Bowel Disease.

Sen P, Uday S Diagnostics (Basel). 2025; 15(5).

PMID: 40075827 PMC: 11899547. DOI: 10.3390/diagnostics15050580.

Evaluation of the effects of bisphosphonate therapy on the temporomandibular joint using cone beam computed tomography.

Sancar B, Gok R, Tunc S Oral Radiol. 2025; .

PMID: 40072733 DOI: 10.1007/s11282-025-00816-3.

Prognostic factors influencing implant survival and marginal bone loss in patients with osteoporosis or osteopenia medication.

Lee S, Yi Y, Won S, Chang N, Kim J J Korean Assoc Oral Maxillofac Surg. 2025; 51(1):17-25.

PMID: 40017070 PMC: 11880673. DOI: 10.5125/jkaoms.2025.51.1.17.

A review of mathematical modeling of bone remodeling from a systems biology perspective.

Cook C, Lighty A, Smith B, Ford Versypt A Front Syst Biol. 2025; 4.

PMID: 40012834 PMC: 11864782. DOI: 10.3389/fsysb.2024.1368555.

Bone scintigraphy and positron emission tomography in the early diagnosis of MRONJ.

Pergolini D, Mohsen M, Tenore G, Palaia G, Magnifico L, Del Vecchio A Open Med (Wars). 2025; 20(1):20251143.

PMID: 39989613 PMC: 11843161. DOI: 10.1515/med-2025-1143.

References

Smith M, McGovern F, Zietman A, Fallon M, Hayden D, Schoenfeld D . Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001; 345(13):948-55. DOI: 10.1056/NEJMoa010845. View

Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M . Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc. 2007; 55(5):752-7. DOI: 10.1111/j.1532-5415.2007.01161.x. View

Penning-van Beest F, Goettsch W, Erkens J, Herings R . Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006; 28(2):236-42. DOI: 10.1016/j.clinthera.2006.01.002. View

Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19):1458-68. DOI: 10.1093/jnci/94.19.1458. View

Smith M, Eastham J, Gleason D, Shasha D, Tchekmedyian S, Zinner N . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003; 169(6):2008-12. DOI: 10.1097/01.ju.0000063820.94994.95. View

Rittmaster R, Bolognese M, Ettinger M, Hanley D, Hodsman A, Kendler D . Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 2000; 85(6):2129-34. DOI: 10.1210/jcem.85.6.6614. View

Coco M, Glicklich D, Faugere M, Burris L, Bognar I, Durkin P . Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003; 14(10):2669-76. DOI: 10.1097/01.asn.0000087092.53894.80. View

Gilchrist N, Frampton C, Acland R, Nicholls M, March R, Maguire P . Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2007; 92(4):1385-90. DOI: 10.1210/jc.2006-2013. View

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

10.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A . Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007; 41(1):122-8. DOI: 10.1016/j.bone.2007.03.011. View

11.

Odvina C, Zerwekh J, Rao D, Maalouf N, Gottschalk F, Pak C . Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2004; 90(3):1294-301. DOI: 10.1210/jc.2004-0952. View

12.

Finkelstein J, Hayes A, Hunzelman J, Wyland J, Lee H, Neer R . The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003; 349(13):1216-26. DOI: 10.1056/NEJMoa035725. View

13.

Compston J, Watts N . Combination therapy for postmenopausal osteoporosis. Clin Endocrinol (Oxf). 2002; 56(5):565-9. DOI: 10.1046/j.1365-2265.2002.01536.x. View

14.

Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman R, Delmas P . Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 2000; 82(4):858-64. PMC: 2374389. DOI: 10.1054/bjoc.1999.1012. View

15.

Boivin G, Chavassieux P, Santora A, Yates J, Meunier P . Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000; 27(5):687-94. DOI: 10.1016/s8756-3282(00)00376-8. View

16.

Hewitt R, Lissina A, Green A, Slay E, Price D, Sewell A . The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2004; 139(1):101-11. PMC: 1809263. DOI: 10.1111/j.1365-2249.2005.02665.x. View

17.

Clemons M, Dranitsaris G, Ooi W, Yogendran G, Sukovic T, Wong B . Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol. 2006; 24(30):4895-900. DOI: 10.1200/JCO.2006.05.9212. View

18.

Karam R, Camm J, McClung M . Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med. 2007; 357(7):712-3. View

19.

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J . Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343(9):604-10. DOI: 10.1056/NEJM200008313430902. View

20.

Hortobagyi G, Theriault R, Lipton A, Porter L, Blayney D, Sinoff C . Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998; 16(6):2038-44. DOI: 10.1200/JCO.1998.16.6.2038. View